"Prednisolone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
| Descriptor ID |
D011239
|
| MeSH Number(s) |
D04.210.500.745.432.769.795
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Prednisolone".
Below are MeSH descriptors whose meaning is more specific than "Prednisolone".
This graph shows the total number of publications written about "Prednisolone" by people in this website by year, and whether "Prednisolone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 3 | 3 |
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 1 | 2 |
| 2000 | 1 | 1 | 2 |
| 2001 | 3 | 2 | 5 |
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 3 | 3 |
| 2011 | 0 | 5 | 5 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 6 | 6 |
| 2020 | 1 | 2 | 3 |
| 2021 | 2 | 1 | 3 |
| 2023 | 0 | 1 | 1 |
| 2024 | 2 | 0 | 2 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prednisolone" by people in Profiles.
-
Corticosteroids in severe alcohol-associated hepatitis. Not so fast: A systematic review of randomized controlled trials. Hepatology. 2025 Nov 01; 82(5):1241-1255.
-
A Case of IgG4-Related Disease Manifesting as Extensive Abdominal Periarteritis and Membranous Nephropathy, Successfully Controlled with Low-Dose Steroid Therapy without Relapse or Complications. Nephron. 2025; 149(4):213-221.
-
Design and rationale of MYOFLAME-19 randomised controlled trial: MYOcardial protection to reduce post-COVID inFLAMmatory heart disease using cardiovascular magnetic resonance Endpoints. J Cardiovasc Magn Reson. 2025; 27(1):101121.
-
The genetic and clinical characteristics and effects of Canakinumab on cryopyrin-associated periodic syndrome: a large pediatric cohort study from China. Front Immunol. 2023; 14:1267933.
-
Romidepsin antagonism with CHOEP. Leukemia. 2023 05; 37(5):1160-1161.
-
Prednisolone rescues Duchenne muscular dystrophy phenotypes in human pluripotent stem cell-derived skeletal muscle in vitro. Proc Natl Acad Sci U S A. 2021 07 13; 118(28).
-
Diagnostic and Therapeutic Challenge. Retina. 2021 Jul 01; 41(7):1570-1576.
-
Immune thrombocytopenia following multisystem inflammatory syndrome in children (MIS-C) - a case series. Pediatr Hematol Oncol. 2021 Oct; 38(7):663-668.
-
Calcium-independent phospholipase A2 inhibitor produces an analgesic effect in a rat model of neuropathic pain by reducing central sensitization in the dorsal horn. Neurol Res. 2021 Aug; 43(8):683-692.
-
Herpetic Eye Disease Study: A Controlled Trial of Topical Corticosteroids for Herpes Simplex Stromal Keratitis. Ophthalmology. 2020 04; 127(4S):S5-S18.